Good points. You have to think that RVX will have the complete synopsis of the baseline for all patients. ie kidney problems, heart issues, diabetes profile etc. along with covid of course and if they have long covid how they react. Maybe some of the patients will have comorbidities. I guess we already have some excellent P values just need to nail them in a trial specifically.  Certainly got the FDA's attention with a BTD and I suspect cooperation going forward. The first BetonMace trial was testing for the wrong outcomes and insufficient P values resulted. I was expecting a $20 stock back then but missed P values being tested. Roound 2 will be able to piggyback off this information and other reported results. Can't worry about Big Pharma's subterfuge. They will try to influence any way they can. Spitballing as well.